NettetA new biopharmaceutical startup, ACELYRIN, that launched this week is on the hunt for new immunological therapies that it can bring to market. The company just closed a round backed by Westlake Village BioPartners, a two-year-old venture capital fund that recently raised $500 million. Flush with an undisclosed amount of cash, ACELYRIN is ... Nettet14. nov. 2024 · Kim is joining Woodland Hills, California-based Acelyrin from synthetic biotechnology company Zymergen, where she was chief legal officer and head of corporate development. The company was sold to ...
ACELYRIN Company Profile Management and Employees List
NettetACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and … NettetMina Kim, Acelyrin Inc: Profile and Biography - Bloomberg Markets Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, … french word trois
Biopharma and Biotech News ACELYRIN
NettetOur Story at ACELYRIN, an Innovative Biopharma Company Building a New Kind of Biopharma Company We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care. Our Values Leading with Courage Courage Quickly solving … NettetMina Kim #218891 License Status: Active Address: Zymergen, 5980 Horton St, Ste 105, Emeryville, CA 94608-2056 Phone: Not Available Fax: Not Available Email: Not … Nettet7. apr. 2024 · The Company's lead technologies are for the healing and restoration of bone and other tissues. Its lead products are based on recombinant human platelet-derived growth factor BB (rhPDGF-BB). In March 2013, BioMimetic Therapeutics was acquired by Wright Medical Group. The valuation of BioMimetic Therapeutics was $190 million. fastype shortcut download